NICE says yes to Alcon's Jetrea
This article was originally published in Scrip
Executive Summary
Alcon/ThromboGenic's Jetrea (ocriplasmin) is soon to be the first drug routinely available on England's National Health Service for treating vitreomacular traction and macular hole. NICE, the health technology appraisal institute, for England and Wales has issued final draft guidance recommending the product.